Nigeria has made a notable advancement in its battle against HIV following the arrival of a new long-lasting injectable medication aimed at preventing infection.
The Federal Ministry of Health and Social Welfare’s National AIDS, Viral Hepatitis and STIs Control Programme (NASCP) reported that the initial delivery of Long-Acting Injectable Lenacapavir (LEN) for Pre-Exposure Prophylaxis (PrEP) was received on March 10, 2026.
In contrast to conventional daily oral PrEP, the injectable offers extended protection, which specialists believe may enhance adherence among people at risk for HIV infection.
The initiative, backed by the Global Fund, aims to broaden prevention choices and enhance service accessibility, especially for groups struggling with daily medication adherence.
“With the arrival of Long-Acting Injectable Lenacapavir, Nigeria is expanding prevention choices and strengthening service delivery to reduce new infections and improve health outcomes,” NASCP stated.
Dr. Adebobola Bashorun, Federal Director and National Coordinator of NASCP, stated that the launch highlights the government’s dedication to utilizing innovative methods to combat HIV, improve prevention, testing, treatment, and care, and work towards eliminating HIV as a public health concern.
NASCP representatives stated that the medication will be systematically incorporated into the national HIV prevention initiative in partnership with stakeholders to guarantee safe and effective implementation
